Translate Bio Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Translate Bio's estimated annual revenue is currently $0.2M per year.
- Translate Bio's estimated revenue per employee is $2,070
- Translate Bio has 115 Employees.
- Translate Bio grew their employee count by 32% last year.
- Translate Bio currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$75.6M||577||N/A||N/A|
What Is Translate Bio?
Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company's RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS).keywords:N/A
Number of Employees
Employee Growth %
|Richard Wooster||Chief Scientific Officer||Email Available|
|Paul Burgess||General Counsel|
|Michelle Grossman||Clinical Trial Manager||Email Available|
|Will Caron||Manager of FP&A||Email Available|
|Christian Cobaugh||Senior Director, Research Discovery & Process Development|
|Caroline O'Hara||Director Clinical Operations|
|Gang Sun||Director and Head, DMPK|
|Florence Chan||Director, Human Resources|
|Robert Meyer||Director (corparate board member)|
|Ann Barbier||Chief Medical Officer|
Translate Bio News
“At Translate Bio, we recognize the importance of developing scalable manufacturing processes in this innovative field and have made this a ...
Translate Bio , a clinical-stage biotech company developing therapies based on synthetic mRNA, said Monday night that it was dropping one of ...
In a pipeline update, Translate Bio (NASDAQ:TBIO) announces that it will prioritize its pulmonary disease programs, including cystic fibrosis ...
Translate Bio Executive Hires
|2017-11-07||Ann Barbier||Chief Medical Officer||Article|
|2018-05-24||John Schroer||Chief Financial Officer||Article|